Who are Alprostadil Liposomes for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): methotrexate + misoprostol, Misoprostol, modified-release pessary, Misoprostol Pill, Mifepristone + Misoprostol, mifepristone and misopristol, Misoprostol (given vaginally).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alprostadil-liposomes-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Alprostadil Liposomes for Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alprostadil Liposomes for Injection (Alprostadil Liposomes for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vasodilator. Area: Cardiovascular.

phase 2 vasodilator prostaglandin E1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Alprostadil Liposomes for Injection (Alprostadil Liposomes for Injection) — Guangzhou Yipinhong Pharmaceutical CO.,LTD. vasodilation via prostaglandin E1 receptor agonism

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Alprostadil Liposomes for Injection TARGET	Alprostadil Liposomes for Injection	Guangzhou Yipinhong Pharmaceutical CO.,LTD	phase 2	vasodilator	prostaglandin E1 receptor
methotrexate + misoprostol	methotrexate + misoprostol	Wiebe, Ellen, M.D.	marketed	Antimetabolite + gastroprotective agent combination	Dihydrofolate reductase (methotrexate); prostaglandin E1 receptor (misoprostol)
Misoprostol, modified-release pessary	Misoprostol, modified-release pessary	Tampere University Hospital	marketed	Prostaglandin analogue	Prostaglandin E1 receptor (EP receptor)
Misoprostol Pill	Misoprostol Pill	University of North Carolina, Chapel Hill	marketed	Prostaglandin analog	Prostaglandin E1 receptor (EP receptor)
Mifepristone + Misoprostol	Mifepristone + Misoprostol	Gynuity Health Projects	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor)
mifepristone and misopristol	mifepristone and misopristol	Hadassah Medical Organization	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR) and prostaglandin E1 receptor (EP receptor)
Misoprostol (given vaginally)	Misoprostol (given vaginally)	Hawler Medical University	marketed	Prostaglandin analogue	Prostaglandin E1 receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vasodilator class)

Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 drug in this class
Hvidovre University Hospital · 1 drug in this class
United States Naval Medical Center, San Diego · 1 drug in this class
yuanli Zhao · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alprostadil Liposomes for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/alprostadil-liposomes-for-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab